Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2233034 | 0.76 | MEN1 (0.39) | LMNATHRB | |
| SCHEMBL25337067 | 0.76 | LMNA (0.38) | LMNATHRB | |
| SCHEMBL2234984 | 0.75 | — | — | |
| SCHEMBL2232314 | 0.74 | THRB (0.32) | LMNATHRB | |
| SCHEMBL6666446 | 0.74 | LMNA (0.45) | LMNATHRB | |
| SCHEMBL7695727 | 0.73 | DNM1 (0.41) | LMNATHRB | |
| SCHEMBL2058496 | 0.70 | LMNA (0.41) | LMNATHRB | |
| SCHEMBL7572420 | 0.68 | LMNA (0.50) | LMNATHRB | |
| SCHEMBL2234084 | 0.67 | PPARD (0.44) | LMNA | |
| SCHEMBL3338817 | 0.67 | FDPS (0.31) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1973923-B1 | INTERMEDIATE COMPOUND OF TECHNETIUM NITRIDE COMPLEX FOR RADIODIAGNOSTIC IMAGING | NIHON MEDIPHYSICS CO LTD (JP) | 2011-08-17 | — | — | EP | claimed |
| US-20100160615-A1 | INTERMEDIATE COMPOUND OF TECHNETIUM NITRIDE COMPLEX FOR RADIODIAGNOSTIC IMAGING | NIHON MED-PHYSICS CO., LTD. (JP) | 2010-06-24 | — | — | US | claimed |
| US-8182789-B2 | Intermediate compound of technetium nitride complex for radiodiagnostic imaging | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2012-05-22 | — | — | US | disclosed |
| EP-1973923-B1 | INTERMEDIATE COMPOUND OF TECHNETIUM NITRIDE COMPLEX FOR RADIODIAGNOSTIC IMAGING | NIHON MEDIPHYSICS CO LTD (JP) | 2011-08-17 | — | — | EP | disclosed |
| US-20100160615-A1 | INTERMEDIATE COMPOUND OF TECHNETIUM NITRIDE COMPLEX FOR RADIODIAGNOSTIC IMAGING | NIHON MED-PHYSICS CO., LTD. (JP) | 2010-06-24 | — | — | US | disclosed |
| EP-1973923-A1 | INTERMEDIATE COMPOUND OF TECHNETIUM NITRIDE COMPLEX FOR RADIODIAGNOSTIC IMAGING | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007083395-A1 | INTERMEDIATE COMPOUND OF TECHNETIUM NITRIDE COMPLEX FOR RADIODIAGNOSTIC IMAGING | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160615-A1 | INTERMEDIATE COMPOUND OF TECHNETIUM NITRIDE COMPLEX FOR RADIODIAGNOSTIC IMAGING | MEN1, NCDN, C1R | LMNA 2957/4885THRB 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.